Overall, sample sizes for the placebo-dosed specimens are much smaller than sifalimumab-dosed specimens, so trends should be interpreted with caution until confirmed in a larger trial.
The placebo-dosed muscle specimens have a more defined difference in IFNGS neutralisation between 15% and greater MMT8 improvers and less than 15% MMT8 improvers, although it is restricted to between20%and40%40% target modulation thresholds.
As a result of viral replication, pronounced inflammation as well as necrosis and fibrosis of myocardial tissue were observed in hematoxylin-eosin and sirius red-stained heart specimens, respectively, in placebo-treated animals on day 28 p. i.. CVB3 also completely destroyed the exocrine pancreas tissue.
Important limitations of this study are the single dose design, absence of a placebo gel group, reliance on CVL specimens alone, and small sample size.
We analyzed biomarker concentrations in specimens from the treatment versus placebo arms at baseline (before the study drug delivery) and day 2 (after at least one dose of the study drug).
The neutralisation of the IFNGS was represented in a heat map for each patient at days 28, 56 and 98 post-administration in blood and day 98 in muscle specimens with either sifalimumab or placebo (figure 2).
The cartilage specimens from the dogs treated with placebo exhibited modifications that are typical of OA.
An international, 16-week, randomized, double-blind, placebo-controlled, parallel group study investigating the effect of roflumilast 500 μg once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimens, sputum and blood serum (clinical trial identifier: NCT01509677).
An international, 16-week, randomized, double-blind, placebo-controlled, parallel-group study investigating the effects of roflumilast 500 μg once-daily versus placebo on inflammatory parameters in bronchial biopsy tissue specimens, sputum and blood serum.
